2nd Quarter - Report

ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY

Firm
Client
Income
—
Expenses
$262,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Support for increased FDA funding

LobbyistCovered position, as disclosed
REGINIA GRAYSON BENJAMIN —
LAUREN LEA FULLER —

Contacted: Federal Trade Commission (FTC); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries,Biosimilar naming, Medicare Part D

LobbyistCovered position, as disclosed
REGINIA GRAYSON BENJAMIN —
LAUREN LEA FULLER —
ADAM PARKER NELSON New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Federal Trade Commission (FTC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6 (114th)

Pharmacy PHA

Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy

LobbyistCovered position, as disclosed
REGINIA GRAYSON BENJAMIN —
LAUREN LEA FULLER —
ADAM PARKER NELSON New —

Contacted: Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.